Many other lines of evidence illustrate the relevance of IL-17 in human barrier health: Mutations in genes involved in the IL-17/IL-23 axis have been identified as risk factors for psoriasis [77] ankylosing spondylitis [78], and IBD [79]. This evidence concerns the gene IL17A and inflammatory bowel disease.